India, June 15 -- Context Therapeutics Inc. (CNTX) on Monday reported positive interim Phase 1 data for its investigational therapy CTIM-76 in patients with advanced, late-line platinum-resistant ovarian cancer (PROC). The company's shares were up more than 6% in pre-market trading.
The data, based on a May 29, 2026 cutoff from the ongoing Phase 1 study, included patients with ovarian, testicular and endometrial cancers who had received a median of seven prior lines of therapy. About 44% of patients had liver metastases.
Among seven evaluable PROC patients, CTIM-76 achieved a confirmed overall response rate of 29%, with two patients recording partial responses. The disease control rate was 57%, with four of seven patients achieving either...